NVCT Nuvectis Pharma, Inc.
USHealthcareAs of 2026-07-10 16:00
Why NVCT matters now
Nuvectis Pharma, Inc. (NVCT) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.35 with -3.37% on the session and $486.9M in market capitalization; recent performance reads 1-month +34.17% and YTD +83.05%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-6.0M, and EPS of $-0.26. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -5.0%.
The latest indexable market news headline is "Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $13.00; recent insider activity includes Kaplan Matthew L. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
22.76
P/S
0.00
EV/EBITDA
-12.17
DCF Value
$1.18
FCF Yield
-5.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.8%
ROA
-106.9%
ROIC
-198.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-6.0M | $-0.26 |
| Q4 2025 | $0.00 | $-7.3M | $-0.31 |
| FY 2025 | $0.00 | $-26.4M | $-1.32 |
| Q3 2025 | $0.00 | $-7.5M | $-0.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$13.00
Target (Median)
$13.00
Target Range
$13.00 - $13.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.07
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.